Neural Regeneration Research ›› 2021, Vol. 16 ›› Issue (7): 1397-1398.doi: 10.4103/1673-5374.300986

Previous Articles     Next Articles

Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer’s disease: new biomarkers for diagnosis and disease progression?

Rosa Maria Corbo, Rita Businaro, Daniela Scarabino*   

  1. Department of Biology and Biotechnology, Sapienza University, Rome, Italy (Corbo RM)
    Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy (Businaro R) 
    CNR Institute of Molecular Biology and Pathology Rome, Italy (Scarabino D) 
  • Online:2021-07-15 Published:2021-01-07
  • Contact: Daniela Scarabino, PhD, daniela.scarabino@cnr.it.
  • Supported by:
    The present work was supported by Sapienza University of Rome (2017/2018 grants allotted to RB and RMC).

    We wish to thank E. Mantuano, M. Peconi, E. Maggi, F. Armeli and M. Morello for their contributions, K.A. Britsch for checking the manuscript style.

PDF

100

Abstract: Alzheimer’s disease and mild cognitive impairment biomarkers: Alzheimer’s disease (AD) is a progressive neurodegenerative disease of advancing age. It affects around 47 million people in the world and the number is estimated to increase to 152 million by 2050. Someone develops dementia every three seconds and the current annual cost of dementia is estimated at US $1 trillion, a figure set to double by 2030 (Alzheimer’s Disease International, 2019).